Equities analysts predict that Theravance Biopharma, Inc. (NASDAQ:TBPH) will report ($1.15) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Theravance Biopharma’s earnings, with the lowest EPS estimate coming in at ($1.16) and the highest estimate coming in at ($1.14). Theravance Biopharma posted earnings of ($1.36) per share during the same quarter last year, which suggests a positive year over year growth rate of 15.4%. The firm is scheduled to report its next earnings report on Monday, February 26th.
On average, analysts expect that Theravance Biopharma will report full year earnings of ($4.84) per share for the current financial year, with EPS estimates ranging from ($5.01) to ($4.49). For the next financial year, analysts forecast that the company will post earnings of ($4.44) per share, with EPS estimates ranging from ($4.75) to ($4.17). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Theravance Biopharma.
Several research firms have recently weighed in on TBPH. ValuEngine cut shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, August 16th. Robert W. Baird reissued a “sell” rating and issued a $22.00 target price on shares of Theravance Biopharma in a research note on Wednesday, November 1st. BidaskClub cut Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Finally, Evercore ISI started coverage on Theravance Biopharma in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $45.00 target price on the stock. Four analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $41.86.
WARNING: “-$1.15 Earnings Per Share Expected for Theravance Biopharma, Inc. (TBPH) This Quarter” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/11/15/1-15-earnings-per-share-expected-for-theravance-biopharma-inc-tbph-this-quarter.html.
In other news, SVP Frank Pasqualone bought 4,000 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was bought at an average cost of $26.34 per share, for a total transaction of $105,360.00. Following the completion of the acquisition, the senior vice president now owns 213,180 shares in the company, valued at approximately $5,615,161.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Bradford J. Shafer sold 14,670 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total transaction of $451,395.90. Following the sale, the executive vice president now owns 134,327 shares of the company’s stock, valued at $4,133,241.79. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in Theravance Biopharma by 3.6% in the second quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock worth $144,972,000 after buying an additional 126,393 shares during the period. Vanguard Group Inc. increased its stake in shares of Theravance Biopharma by 3.8% during the second quarter. Vanguard Group Inc. now owns 3,197,277 shares of the biopharmaceutical company’s stock valued at $127,379,000 after purchasing an additional 116,981 shares in the last quarter. State Street Corp increased its stake in shares of Theravance Biopharma by 2.2% during the second quarter. State Street Corp now owns 889,682 shares of the biopharmaceutical company’s stock valued at $35,443,000 after purchasing an additional 19,428 shares in the last quarter. Northern Trust Corp increased its stake in shares of Theravance Biopharma by 6.1% during the second quarter. Northern Trust Corp now owns 530,049 shares of the biopharmaceutical company’s stock valued at $21,117,000 after purchasing an additional 30,611 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Theravance Biopharma by 5.8% during the first quarter. Geode Capital Management LLC now owns 330,280 shares of the biopharmaceutical company’s stock valued at $12,160,000 after purchasing an additional 18,177 shares in the last quarter. Institutional investors own 84.55% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Theravance Biopharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Theravance Biopharma Inc. and related companies.